2025
March
Finding the right combination: new insights in anti-PD-1 plus anti-CTLA-4 or anti-LAG3
March 19, 2025
Treatment with checkpoint blockades alone or in various combinations can induce strong antitumor responses, but identifying which treatment or combination will work best for each individual patient is still a challenge. In work recently published in Cancer Cell, Li and Zandberg et al. evaluated results and T cell dynamics from a neoadjuvant trial...
Tumoral RNA splicing: source of neoantigens for off-the-shelf therapies?
March 12, 2025
Immunotherapies targeting tumor-specific antigens (TSAs) derived from somatic mutations have limited potential in tumors with low mutational burdens. A recently discovered source of TSAs are cancer-specific splicing events (neojunctions; NJs), which have the potential to induce CD8+ T cell responses. What remains unknown is whether these NJs are conserved spatially and temporally across...
AACR IO 2025
March 5, 2025
The ACIR team attended the newly established AACR IO meeting held on February 23-26, 2025 in Los Angeles, CA, USA. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. Welcome Keynote AddressesJim AllisonArlene Sharpe Neoantigens and ERVsCatherine WuChristopher KlebanoffAlena GrosSebastian AmigorenaGeorge Kassiotis CytokinesChristopher...
